The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the first new type of medication in decades that alleviates symptoms without common side effects. Available by late October, the drug will cost $1,850 monthly before insurance and rebates.
Related Posts
Hope for progressive regulatory regime: Amazon
Amazon India’s senior VP, Amit Agarwal, amidst regulatory scrutiny, affirms compliance and advocates for progressive e-commerce policies. He emphasizes investments in logistics and infrastructure, not […]
Income tax relief for the middle class! Top 5 income tax changes from Budget 2025 you should know
- staff
- February 1, 2025
- 0
Budget 2025 income tax slab changes FY 2025-26: Finance Minister Nirmala Sitharaman presented Budget 2025 addressing the middle class by increasing the rebate limit under […]